nivolumab
bms,mereo biopharmaceutical
['nivo', 'biomarker', 'marker ', 'bms', 'bmsnews']
 these interim biomarker data from etig+nivo combination therapy demonstrated robust target engagement and evidence of dual tigit/pd-1 blockade as seen by decreases in tigithi cells (e.g., tregs) 
No investment advice and tweets are my opinion or research that I have https://t.co/2d68PpO8Ou your own research before investing in stock market.